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Abstract
Genetic variation in nicotinic acetylcholine receptor subunit genes (nAChRs) is associated with lung function level and
chronic obstructive pulmonary disease (COPD). It is unknown whether these variants also predispose to an accelerated lung
function decline. We investigated the association of nAChR susceptibility variants with lung function decline and COPD
severity. The rs1051730 and rs8034191 variants were genotyped in a population-based cohort of 1,226 heavy smokers
(COPACETIC) and in an independent cohort of 883 heavy smokers, of which 653 with COPD of varying severity (LEUVEN).
Participants underwent pulmonary function tests at baseline. Lung function decline was assessed over a median follow-up
of 3 years in COPACETIC. Current smokers homozygous for the rs1051730 A-allele or rs8034191 G-allele had significantly
greater FEV1/FVC decline than homozygous carriers of wild-type alleles (3.3% and 4.3%, p = 0.026 and p= 0.009,
respectively). In the LEUVEN cohort, rs1051730 AA-carriers and rs8034191 GG-carriers had a two-fold increased risk to suffer
from COPD GOLD IV (OR 2.29, 95% confidence interval [CI] = 1.11–4.75; p = 0.025 and OR= 2.42, 95% [CI] = 1.18–4.95;
p = 0.016, respectively). The same risk alleles conferred, respectively, a five- and four-fold increased risk to be referred for
lung transplantation because of end-stage COPD (OR= 5.0, 95% [CI] = 1.68–14.89; p = 0.004 and OR= 4.06, 95% [CI] = 1.39–
11.88; p = 0.010). In Europeans, variants in nAChRs associate with an accelerated lung function decline in current smokers
and with clinically relevant COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is characterized
by progressive airflow limitation as reflected by an accelerated
decline in forced expiratory volume in one second (FEV1) [1].
Unfortunately, symptoms in COPD often only become apparent
after a significant loss of lung function, thereby delaying diagnosis
and negatively influencing prognosis. Smoking is by far the most
important risk factor for COPD [1]. Although cigarette smokers
have a larger FEV1 decline than non-smokers, only 10–20% of
them develop COPD [2]. Additional susceptibility factors predic-
tive of an accelerated lung function decline thus need to be
identified, allowing the implementation of appropriate strategies to
prevent patients from developing severe COPD.
Genetic predisposition to COPD development is actively being
explored [3]. For many years, uncommon mutations in the gene
encoding the alpha 1-antitrypsin protein represented the only
established genetic risk factor for severe, early-onset COPD [4].
Recently, several genome-wide association studies (GWAS)
identified multiple novel genetic risk factors [5–7]. One of these
at-risk loci is located on chromosome 15q24/25 in a region that
contains the nicotinic acetylcholine receptor subunit genes
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(nAChRs) [7]. Interestingly, nAChR variants have also been
associated with smoking addiction [8–11], peripheral arterial
disease [12], lung cancer [12–14] and emphysema [15] indicating
that the nAChR locus is implicated in the development of smoking-
related conditions.
Although it is widely accepted that COPD results from a
progressive decline in lung function [16], it has not yet been
established whether nAChR variants predisposing to COPD are
also associated with an accelerated lung function decline. In
addition, it is currently unclear how smoking behavior may
interact with this genetic locus on disease progression. We
therefore assessed whether rs1051730 and rs8034191, two variants
in the nAChR locus, were associated with the decline in FEV1,
FEV1/FVC and MEF50 over 3 years in subjects from a large
population-based cohort (COPACETIC, n= 1,226). As proof of
concept, we additionally assessed the predictive value of our
findings in an independent group of heavy smokers (LEUVEN),
consisting of healthy smokers (n = 230) and patients diagnosed
with COPD of varying stages of severity (GOLD I–IV, n= 653).
Materials and Methods
Study subjects
The COPACETIC cohort included 1,226 Dutch participants
from the NELSON lung cancer screening trial recruited by the
University Medical Centers of Groningen and Utrecht [17]. In
brief, all participants were male heavy smokers ($20 or more
pack-years), aged between 50–75 years and fit enough to undergo
surgery.
The LEUVEN cohort included 366 Belgian participants of the
Dutch-Belgian randomized lung cancer screening trial (NELSON)
who were recruited from the general population of 14 municipal-
ities around LEUVEN and who were not previously diagnosed
with COPD. In addition, 517 COPD patients were included at the
outpatient clinic of the University Hospital Gasthuisberg in
Leuven. Of these 517 subjects, 123 were listed for lung
transplantation because of disabling end-stage COPD [18]. The
883 LEUVEN participants were all heavy smokers, matched for
smoking history (.15 pack-years) and age (.50 years). All
LEUVEN participants self-declared Belgian-Flemish ethnicity for
three generations [19].
Participants from both COPACETIC and LEUVEN, all of
Caucasian ancestry, provided written informed consent. The
complete inclusion criteria for COPACETIC and LEUVEN are
described in detail in Material S1.
Ethics statement
The UZ LEUVEN Medical Ethics Committee (Leuven,
Belgium) and the University Medical Center Utrecht Institutional
Review Board both approved the study protocol.
Pulmonary function testing
All participants underwent pulmonary function tests with
standardized equipment according to the American Thoracic
Society (ATS) and European Respiratory Society (ERS) guidelines
[20]. To investigate the influence of genetic variability on decline
in FEV1 and FEV1/FVC, pulmonary function tests were
performed at inclusion and after three years of follow-up in
COPACETIC. We also evaluated the decline in MEF50, which
represents the maximal expiratory flow at 50% FVC and may
reflect changes in the smaller peripheral airways [20]. Bronchial
obstruction was established as a post-bronchodilator FEV1/FVC
ratio of ,0.70 in LEUVEN and as a pre-bronchodilator FEV1/
FVC ratio of ,0.70 in COPACETIC [1]. Severity was staged by
FEV1 expressed as % predicted according to the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) classification [1].
Genotyping
Two variants in the 15q24/25 locus, rs1051730 and rs8034191,
were selected based on previous GWAS for COPD and lung
cancer [7,12–14]. Genotyping was conducted in analogy to a
previously published study, in which we established an association
between a single SNP, rs1051730, and the risk of COPD and
emphysema [15]. In particular, COPACETIC genotypes were
extracted from Human610-Quad BeadChip data generated in the
COPACETIC GWAS (Illumina Inc., San Diego, CA, USA),
whereas LEUVEN participants were genotyped in a blinded
manner using iPLEX technology on a MassARRAY Compact
Analyser (Sequenom Inc., San Diego, CA, USA). A more detailed
description is given in Material S2.
Statistical Analysis
Means and standard deviations (SD) were calculated for
normally distributed variables, and medians and interquartile
ranges for non-normally distributed variables. Chi-square tests
were used to test for differences in demographics and nicotine-
addiction related variables between genotypes. Multivariate
regression analyses correcting for age, smoking status and study
center were performed to assess the association of the genotypes
with smoking behavior. In both cohorts (COPACETIC and
LEUVEN), all analyses for both variants were performed without
assuming a specific model of inheritance, i.e., by conducting a
genotypic test.
In COPACETIC, multiple regression analyses were performed
to test the association of rs1051730 and rs8034191 with changes in
FEV1/FVC, FEV1 and MEF50 over time. To differentiate
between genetic variability in lung function decline and a
genetically determined lower lung function level, adjustments for
baseline FEV1, FEV1/FVC and MEF50 were made. In particular,
adjustments were made for study center, age, height, smoking
status (current/former smoker), pack-years, years in study and
baseline FEV1/FVC, FEV1, MEF50. To test whether the effect of
genotype differed according to smoking status, we also inserted an
interaction between genotype and smoking status. We particularly
assessed the interaction with smoking status since this variable is
the most important differentiating smoking-related variable in our
study population of heavy smokers (with .20 pack-years of
smoking at inclusion). Change in lung function was calculated by
subtraction of the baseline lung function values from the predicted
follow-up values derived from the multiple regression analyses. In
addition, we calculated the observed power to discover a
significant association of genotypes, smoking status (current versus
former) and the genotype*smoking status interaction term with
lung function decline. The methods and results of power
calculations are provided in Material S3. In COPACETIC, the
p-value threshold for significance adjusted for testing three clinical
variables (decline in FEV1/FVC, FEV1 and MEF50) using the
Bonferroni correction method, resulting in a significance threshold
of p,0.0167.
In LEUVEN, the relationship between rs1051730 or rs8034191
genotypes and GOLD stage was assessed by chi-square analysis.
The association between genotypes and the risk of developing very
severe COPD (GOLD IV) was confirmed via multinomial logistic
regression analysis, while correcting for age, height, sex, pack-
years and years-quit for former smokers. In addition, given the
extensive heterogeneity in degree of functional impairment among
COPD patients, even with the same level of airflow obstruction,
we classified the LEUVEN subjects in three clinical subgroups: (i)
nAChR Variants Associate with Lung Function
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asymptomatic smokers, defined as heavy smokers that do not
report respiratory symptoms and are therefore not diagnosed with
COPD, (ii) ambulatory COPD patients, defined as patients with
well-established COPD routinely attending the outpatient pulmo-
nary clinic, and (iii) patients listed for lung transplantation because
of the severe repercussion of COPD for their daily life activities
and life expectancy (,18 months). Differences between these
subgroups were assessed using a Pearson’s chi-square analysis. A
multinomial logistic regression analysis to assess the probability of
belonging to any of these clinical subgroups in function of
genotypes was performed, while correcting for age, height, sex,
pack-years and years-quit for former smokers. P-values,0.05 were
considered significant in the LEUVEN cohort. All statistical




In total, 1,226 participants were included in COPACETIC and
883 participants in LEUVEN. Demographics, smoking history,
pulmonary function measurements and the prevalence of COPD
is shown for all COPACETIC and LEUVEN participants in
Table 1. There were no significant differences in pack-years
between former and current smokers (p = 0.188 and p= 0.309 for
COPACETIC and LEUVEN, respectively; data not shown).
Baseline characteristics for the LEUVEN clinical subgroups are
shown in Table 2.
In COPACETIC, genotyping for both rs1051730 and
rs8034191 succeeded in 99% of participants. In LEUVEN
genotyping for rs1051730 and rs8034191 succeeded in 99% and
100%, respectively. Genotype frequencies were similar as observed
in the HAPMAP databases and other studies [7,21]. There was
strong linkage disequilibrium between rs1051730 and rs8034191
in both cohorts (r2 = 0.86 for COPACETIC and r2 = 0.88 for
LEUVEN). Baseline characteristics for LEUVEN and COPA-
CETIC participants according to rs1051730 and rs8034191
genotypes are shown in Table 3 and Table 4.
Association of nAChR variants with nicotine addiction-
related variables
To assess whether rs1051730 and rs8034191 were associated
with nicotine addiction, we tested for association with pack-years,
smoking status (current/former smoker), quit-years in former
smokers (.5, 1–5, ,1 years) and age-started smoking (,14 years,
15–19 years, .20 years) in COPACETIC. No significant
associations were found (Table 3). Moreover, multivariate
regression analysis, correcting for age, smoking status and study
center, showed no significant effect of rs1051730 and rs8034191
on pack-years smoked (p = 0.327 and 0.258, respectively).
Likewise, no significant association between rs1051730 and
rs8034191 genotypes, and smoking status (current/former) or
pack-years was found in LEUVEN (respectively, p = 0.144 and
p= 0.086 for rs1051730, p= 0.211 and P= 0.103 for rs8034191;
Table 4). Multivariate regression analysis, correcting for age,
Table 1. Characteristics for COPACATIC and LEUVEN at baseline and after three-year follow-up for COPACETIC.
COPACETIC LEUVEN
Baseline (n =1,226) Follow-up (n=1,226) (n =883)
Demographics
Age, mean (SD), yr 59.7 (5.3) 62.7 (5.4) 63.9 (8.0)
Male sex, no. (%) 1,226 (100) 1,226 (100) 656 (74.0)
Height, mean (SD), cm 177.5 (6.5) 178.1 (6.3) 169.6 (8.9)
Smoking
Pack-year history, mean (SD), yr 40.7 (17.4) N/A 47.4 (24.8)
Current smokers, no. (%) 753 (61.4) N/A 367 (41.3)
Smoked years, mean (SD), yr 39.6 (8.87) N/A 41.7 (9.0)
Years quit smokers, median (25th–75th percentiles) 8.1 (3.0–9.0) N/A 1.0 (0.0–8.0)
Pulmonary function tests, mean (SD)
FEV1, L 3.33 (0.73) 3.14 (0.72) 1.92 (1.08)
FEV1, % predicted 96.5 (18.4) 93.7 (18.8) 65.4 (32.7)
FVC, L 4.70 (0.79) 4.61 (0.81) 3.36 (1.13)
FVC, % predicted 107.1 (14.6) 106.7 (15.3) 91.9 (24.3)
MEF50, L/s 3.08 (1.45) 2.76 (1.38) 1.52 (1.50)
FEV1/FVC ratio 0.71 (0.10) 0.68 (0.10) 0.54 (0.18)
COPD severity, no. (%)
No Obstruction 682 (55.6) 557 (45.4) 230 (26.0)
GOLD class I 357 (29.1) 430 (35.1) 123 (13.9)
GOLD class II 162 (13.2) 210 (17.1) 183 (20.7)
GOLD class III 24 (2.0) 23 (1.9) 188 (21.2)
GOLD class IV 0 5 (0.4) 159 (18.0)
FEV1: forced expiratory volume in one second; FVC: forced vital capacity; COPD: chronic obstructive pulmonary disease; GOLD: global initiative for chronic obstructive
lung disease; N/A: non-applicable. Percentages are column percentages. Of the LEUVEN participants, 653 subjects were diagnosed with COPD (FEV1/FVC,0.70).
doi:10.1371/journal.pone.0053219.t001
nAChR Variants Associate with Lung Function
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gender and smoking status, showed no significant effects for
rs1051730 and rs8034191 on pack-years smoked (p= 0.133 and
0.140, respectively; data not shown).
Association of nAChR variants with lung function decline
in COPACETIC
Lung function measurements at baseline and after a median
follow-up time of 3 years (interquartile range 2.9–3.1) are provided
in Table 1. Mean FEV1/FVC at baseline was 70.9610.2% and
68.069.6% at follow-up, representing a mean decrease of 2.9%.
Mean decrease of FEV1 and MEF50 were 193 mL and 322 mL/s,
respectively. Baseline lung function measurements stratified for
rs1051730 and rs8034191 are provided in Table 3.
In a multivariate regression analysis to test the association of
both genotypes with lung function decline, the interaction between
rs1051730 and smoking status was significant (p = 0.015 for
interaction term). This indicates that the effect of rs1051730
genotypes differed between current and former smokers. Current
smokers homozygous for the rs1051730 A-allele had a more
pronounced decline in FEV1/FVC compared to current smokers
homozygous for the G-allele (4.3% and 3.3%, p= 0.026, Table 5).
In contrast, former smokers carrying the AA genotype had no such
stronger decline in FEV1/FVC compared to former smoking GG-
carriers (1.5% and 2.4%, p= 0.317, Table 5).
Similar results were obtained for the interaction between
rs8034191 and smoking status (p = 0.002 for interaction term).
Current smokers homozygous for the rs8034191 G-allele showed a
significantly stronger decline of the FEV1/FVC compared to
current smoking participants homozygous for A-alleles (3.3% and
2.7%, p= 0.009). For heterozygotes this decline was 2.9%. As for
rs1051730, former smokers homozygous for the rs8034191 G-
allele had no significant additional FEV1/FVC decline compared
to former smoker homozygous for the A-allele (1.4% and 2.4%,
p= 0.465). When performing similar analyses for FEV1 neither of
the two SNPs was significantly associated with a lower FEV1 at
follow-up (p = 0.964 and 0.857, respectively) and none of the
interactions between SNPs and smoking status were significant
(p = 0.203 and 0.107, respectively).
When analyzing MEF50, a similar effect as observed with
FEV1/FVC was noted (p= 0.047 and 0.036 for rs105170 or
rs8034191, respectively). Smokers homozygous for the rs1051730
A-allele had a 491 mL/s decline in MEF50 compared to a
393 mL/s in GG-carriers (p = 0.083). A similar pattern was found
for smokers carrying the rs8034191 GG genotype (485 mL/s
decline compared to 377 mL/s, p = 0.017) in current smokers. In
heterozygotes the decline was 314 mL/s. For both SNPs there
were no significant differences in former smokers (167 mL/s and
253 mL/s, p= 0.280 and 146 mL/s and 271 mL/s, p = 0.188,
respectively for rs1051730 and rs8034191).
To additionally demonstrate that the association of rs1051730
and rs8034191 with decline in FEV1/FVC and MEF50 in active
smokers was independent of baseline lung function level, we
inserted the interaction term baseline FEV1/FVC*genotype or
MEF50*genotype as a covariate in the regression model. As








Age, mean (SD), yr 62.3 (5.71) 67.6 (8.67) 57.2 (4.69) ,0.001
Male sex, no. (%) 286 (78.1) 305 (77.4) 62 (50.4) ,0.001
Height, mean (SD), cm 172.0 (8.9) 168.6 (8.4) 165.0 (8.5) ,0.001
Smoking
Pack-years history, mean (SD), yr 45.8 (21.8) 52.5 (27.3) 35.5 (19.8) ,0.001
Current smokers, no. (%) 203 (55.8) 157 (40.5) 5 (15.6) ,0.001
Smoked years, mean (SD), yr 40.6 (7.0) 43.2 (10.4) 36.1 (8.2) ,0.001
Years quit smokers, median (25th–75th percentiles) 0.0 (0.0–7.0) 2.0 (0.0–9.0) 3.0 (1.0–6.0) ,0.001
Pulmonary function tests, mean (SD)
FEV1, L 2.91 (0.74) 1.38 (0.63) 0.70 (0.30) ,0.001
FEV1, % predicted 96.4 (18.3) 49.3 (20.1) 25.5 (9.9) ,0.001
FEV1/FVC ratio 0.70 (0.09) 0.45 (0.13) 0.33 (0.08) ,0.001
COPD severity, no. (%)
No Obstruction 218 (59.6) 11 (2.8) 0 (0) ,0.001
GOLD class I 96 (26.2) 27 (6.9) 1 (0.8)
GOLD class II 46 (12.6) 134 (34.0) 3 (2. 4)
GOLD class III 6 (1.6) 157 (39.8) 25 (20.3)
GOLD class IV 0 (0) 65 (16.5) 94 (76.4)
Abbreviations are the same as in Table 1. Percentages are column percentages. The 366 asymptomatic smokers are population-based participants of the Dutch-Belgian
lung cancer screening trial (NELSON). None of them were previously diagnosed with COPD. However, 148 subjects (40.4%) were found to have an obstructive lung
function (based on FEV1/FVC,0.70) at inclusion. Eleven subjects (2%), that were followed-up at the outpatient clinic because of symptoms compatible with COPD, did
not fulfill the criterion of COPD (FEV1/FVC.0.70). Five patients with end-stage COPD were not actively listed for lung transplantation because of their current smoking
status at inclusion.
doi:10.1371/journal.pone.0053219.t002
nAChR Variants Associate with Lung Function
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expected, these analyses did not reveal a significant effect for these
interaction terms (p = 0.225 and p=0.310 for FEV1/FVC and
p= 0.248 and p= 0.172 for MEF50, respectively for rs1051730
and rs8034191). The significance values of the interaction terms
genotype*lung function parameter (FEV1/FVC and MEF50) are
listed in Table 6.
Association between nAChR variants and severity of
COPD
To assess the clinical relevance of an accelerated lung function
decline due to variation in nAChR genes, we studied the association
of rs1051730 and rs8034191 with COPD severity and symptoms
in an independent group of heavy smokers (LEUVEN). A
multinomial logistic regression analysis was performed to assess
the association between both genotypes and the risk of developing
very severe COPD (GOLD IV). AA-carriers of the rs1051730
genotype had a two-fold increased risk (OR 2.29, 95% confidence
interval [CI] = 1.11–4.75; p = 0.025) of suffering from COPD
GOLD IV compared to GG-carriers. Likewise, GG-carriers of
rs8034191 (compared to AA-carriers) had a two-fold increased risk
for GOLD IV versus no COPD (OR 2.42, 95% [CI] = 1.18–4.95;
p = 0.016). No association was observed between rs1051730 or
rs8034191 and lower GOLD stages (p = 0.837, p = 0.406 and
P=0.933, respectively for the association between rs1051730 and
GOLD I, II and III and p= 0.373, p= 0.339 and P=0.633,
respectively for the association between rs8034191 and GOLD I,
II and III).
To establish whether the accelerated lung function decline in at-
risk smokers also influences the severity of disease presentation, we
classified all the LEUVEN subjects in three clinical categories
(Table 2). We observed a significant association between
rs1051730 and the clinical subgroups (p = 0.018; Table 4). Indeed,
carriers of the at-risk AA genotype were twice as frequent in the
most severe COPD group (24.8% in patients with end-stage
COPD versus 15.9% and 11.8% in ambulatory COPD patients
and asymptomatic smokers). Moreover, multinomial logistic
regression revealed that (compared to GG) AA-carriers of the
rs1051730 genotype exhibited an odds ratio of 5.0 (95%
[CI] = 1.68–14.89; p = 0.004) for receiving lung transplantation.
Likewise, AA-carriers had a 1.48-fold increased risk of being an
ambulatory COPD patient (95% [CI] = 0.90–2.42; p = 0.119).
The latter analysis was not significant presumably because some of
the asymptomatic heavy smokers in LEUVEN already developed
COPD (respectively 12.5% and 1.6% exhibited COPD with
GOLD II and III). Similar data were observed for the rs8034191
SNP, as GG-carriers had a 4-fold increased risk of evolving to end-
stage COPD with need of lung transplantation (OR=4.06; 95%
[CI] = 1.39–11.88; p= 0.010) and a 1.56-fold increased risk of















Age, mean (SD), yr 59.6 (6.0) 59.6 (5.3) 59.7 (5.4) 0.952 59.6 (5.7) 59.6 (5.2) 59.8 (5.4.) 0.739
Pack year history, mean (SD), yr 39.3 (15.9) 41.4 (17.4) 40.2 (17.7) 0.301 39.7 (17.4) 41.6 (17.6) 39.9 (17.2) 0.209
Current smokers, no (%) 76 (56.7%) 333 (59.3%) 344 (64.9%) 0.093 75 (56.4%) 341 (60.9%) 337 (63.5%) 0.298
Years quit smoking % (no) 0.307 0.356
0 57.8% (78) 59.4% (337) 64.8% (346) 57.0% (75) 60.9% (344) 63.4% (339)
,1 7.4% (10) 6.4% (35) 7.8% (41) 6.7% (9) 6.5% (35) 7.9 5 (42)
1–5 18.5% (24) 18.5% (102) 14.3% (74) 19.3% (25) 17.5% (97) 15.2% (79)
.5 16.3% (22) 15.7% (88) 13.1% (69) 17.0% (23) 15.2% (84) 13.5% (71)
Age started smoking % (no) 0.491 0.397
,14 years 14.9% (20) 19.2% (118) 17.4% (92) 16.5% (22) 18.8% (111) 16% (87)
15–19 years 70.2% (94) 65.8% (395) 67.7% (359) 67.0% (91) 65.7% (378) 68.4% (368)
.20 14.9% (20) 15.0% (48) 14.9% (79) 16.5% (22) 11.8% (71) 13.7% (76)
Pulmonary function tests,
mean (SD)
FEV1, L 3.26 (0.76) 3.29 (0.73) 3.41 (0.72) 0.013 3.24 (0.74) 3.29 (0.74) 3.41 (0.71) 0.008
FEV1, % predicted 94.4 (19.5) 95.1 (18.5) 98.6 (17.9) 0.003 94.1 (18.8) 95.2 (19.0) 98.6 (17.4) 0.002
FEV1/FVC ratio 0.70 (0.10) 0.71 (0.10) 0.72 (0.107) 0.002 0.71 (0.10) 0.70 (0.11) 0.72 (0.10) 0.002
MEF50, L/s 2.97 (1.44) 2.95 (1.39) 3.25 (1.50) 0.002 2.94 (1.38) 2.96 (1.44) 3.24 (1.47) 0.003
COPD severity, no. (%) 0.004 0.010
No Obstruction 67 (50%) 291 (51.6%) 326 (61.3%) 71 (52.2%) 286 (51.2%) 326 (61.2%)
GOLD class I 38 (28.4%) 181 (32.2%) 138 (26.0%) 39 (28.4%) 176 (31.4%) 143 (26.9%)
GOLD class II 27 (20.1) 74 73 (13.2%) 61 (11.5%) 24 (17.9%) 81 (14.4%) 57 (10.7%)
GOLD class III 2 (1.5%) 17 17 (3.0%) 5 (0.9%) 2 (1.5%) 17 (3.0%) 5 (0.9%)
FEV1: forced expiratory volume in one second; FVC: forced vital capacity; MEF50 maximum expiratory flow when 50% of the FVC has been exhaled; GOLD: global
initiative for chronic obstructive lung disease. Percentages are column percentages. Genotyping succeeded in 1226 (100%) and 1224 (99.8%) COPACETIC participants,
respectively for rs1051730 and rs8034191.
doi:10.1371/journal.pone.0053219.t003
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belonging to the group of ambulatory COPD patients (OR=1.56;
95% [CI] = 0.97–2.51; p= 0.069).
Given the interaction between both nAChR variants and
smoking status in the COPACETIC cohort, we additionally
corrected our multinominal logistic regression analysis in the
LEUVEN cohort for the interaction term rs1051730*smoking
status or rs8034191*smoking status. The interaction was not found
to significantly influence the risk of developing COPD GOLD
stage IV (OR=0.24, 95% [CI] = 0.04–1.37; p = 0.108 for
rs1051730*smoking status and OR=0.25, 95% [CI] = 0.05–
1.30; p = 0.101 for rs8034191*smoking status). Likewise, the
interaction term was not found to significantly influence the
severity of disease presentation (OR=0.47, 95% [CI] = 0.02–10.9;
p = 0.637 for rs1051730*smoking status and OR=0.45, 95%
[CI] = 0.02–10.1; p= 0.618 for rs8034191*smoking status).
Discussion
In the current study, we observed that two common variants in
the nAChR locus on chromosome 15q24/25 affect FEV1/FVC
decline in a population-based sample consisting of heavy smokers
(COPACETIC). To the best of our knowledge, our study is the
first to show an association of the 15q24/25 locus with decline in
lung function over time. Importantly, this genotype-associated
difference in lung function decline was independent of baseline
lung function level, indicating that variants in the nAChR locus are
not merely associated with an inherited lower lung function level,
but also with an accelerated decline in lung function. Remarkably,
no such effect was observed in former smokers. Based on power
calculations, which revealed that our study had respectively 81.9%
and 88.0% power for rs1051730 and rs8034191 to detect a
Table 4. Baseline characteristics for the LEUVEN group according to rs1051730 and rs8034191 genotypes.
rs1051730 rs81034191
AA AG GG P-value GG AG AA P-value
Demographics
Age 63.9 (7.8) 63.4 (8.0) 64.7 (8.0) 0.086 63.5 (7.9) 63.6 (8.0) 64.6 (8.0) 0.234
Pack-years history, mean (SD), yr 45.5 (21.6) 49.6 (26.7) 45.9 (23.9) 0.080 46.2 (22.2) 49.4 (26.6) 45.7 (23.5) 0.103
Current smokers, no (%) 44 (38.3) 170 (47.2) 147 (48.8) 0.144 52 (41.3) 167 (45.5) 146 (50.2) 0.211
Pulmonary function tests,
mean (SD)
FEV1, L, post 1.74 (1.04) 1.93 (1.09) 1.98 (1.07) 0.088 1.77 (1.06) 1.93 (1.08) 1.98 (1.08) 0.146
FEV1, % predicted, post 59.8 (31.6) 65.5 (32.6) 68.1 (33.1) 0.044 60.7 (32.6) 65.6 (32.0) 67.5 (33.4) 0.111
FEV1/FVC ratio, 0.51 (0.18) 0.54 (0.18) 0.55 (0.18) 0.054 0.51 (0.18) 0.54 (0.18) 0.55 (0.18) 0.045
COPD severity, no. (%) 0.444 0.385
No bronchial obstruction 30 (13.1) 106 (46.3) 93 (40.6) 31 (13.5) 109 (47.4) 90 (39.1)
GOLD class I 18 (14.8) 51 (41.8) 53 (43.4) 22 (17.9) 52 (42.3) 49 (39.8)
GOLD class II 27 (15.0) 89 (49.4) 64 (35.6) 28 (15.3) 93 (50.8) 62 (33.9)
GOLD class III 27 (14.4) 85 (45.5) 75 (40.1) 29 (15.4) 86 (45.7) 73 (38.8)
GOLD class IV 33 (21.2) 71 (45.5) 52 (33.3) 36 (22.6) 69 (43.4) 54 (34.0)
Clinical Category, no. (%) 0.018 0.067
Asymptomatic smokers 43 (11.8) 175 (48.2) 145 (39.9) 48 (13.1) 176 (48.1) 142 (38.8)
Ambulatory COPD patients 62 (15.9) 176 (45.1) 152 (39.0) 68 (17.3) 182 (46.2) 144 (36.5)
Patients with end-stage COPD 30 (24.8) 51 (42.1) 40 (33.1) 30 (24.4) 51 (41.5) 42 (34.1)
Genotyping succeeded in 874 (99%) and 883 (100%) LEUVEN participants, respectively for rs1051730 and rs8034191.
doi:10.1371/journal.pone.0053219.t004
Table 5. Lung function decline in COPACETIC according to rs1051730 and rs8034191 genotypes.
rs1051730 rs8034191
FEV1/FVC [%] FEV1 [mL] MEF50 [mL/s] FEV1/FVC [%] FEV1 [mL] MEF50 [mL/s]
Current smoker AA 4.30 (0.82)# 229 (57) 491 (220) Current smoker AA 2.72 (0.87) 246 (52) 377 (232)
AG 2.97 (0.97) 203 (56) 316 (245) AG 2.87 (0.95) 200 (62) 315 (252)
GG 3.30 (0.88) 243 (51) 393 (237) GG 3.31 (0.85)* 232 (56) 485 (211)*
Former smoker AA 1.53 (1.07) 140 (60) 167 (250) Former smoker AA 2.44 (0.89) 171 (58) 271(253)
AG 2.47 (0.99) 180 (56) 289 (233) AG 2.48 (1.00) 180 (58) 281 (236)
GG 2.41 (0.90) 167 (57) 253 (259) GG 1.39 (1.06) 130 (65) 146 (250)
#significant compared to the GG genotype for rs1051730 (p = 0.026).
*significant compared to AA genotype for rs8034191 (p = 0.009 and p= 0.017, respectively for FEV1/FVC and MEF50 decline).
doi:10.1371/journal.pone.0053219.t005
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significant difference in FEV1/FVC decline in former smokers
(Material S3), we believe that the absence of genetic variability in
lung function decline in former smokers is a true negative finding.
Importantly, we also established that the accelerated lung function
decline in rs1051730 AA-carriers and rs8034191 GG-carriers may
be relevant for clinical practice. For instance, compared to GG-
carriers, homozygotes for the rs1051730 A-allele showed a two-
fold increased risk (OR=2.29) to be diagnosed with very severe
COPD GOLD IV and exhibited an OR of 5.0 to have end-stage
COPD with need for lung transplantation [22]. Likewise, GG-
carriers of the rs8034191 genotype had a two-fold increased risk
(OR=2.42) to have GOLD stage IV disease and a four-fold
increased risk (OR=4.06) to be in need of lung transplantation
compared to AA-carriers. Overall, these data suggest that current
smokers carrying two copies of the at-risk alleles in the nAChR
genes have an accelerated lung function decline, which may reflect
susceptibility towards the development of severe COPD. The
association between the same at-risk genotypes and very severe
COPD supports this hypothesis. Future experiments are now
warranted to investigate the association between genetic variation
in the nAChR genes, lung function decline and incident COPD.
The observed associations may be biased for differences in
smoking behavior between the nAChR at-risk and wild type
genotypes. Indeed, recent GWA studies have indicated that the
nAChR risk variants increase the risk of smoking addiction,
presumably by mediating addictive effects in the brain, and
promote more intense smoking, as reflected by a higher level of
tobacco-specific nitrosamines per cigarette smoked in homozygous
carriers of the at-risk alleles [23,24]. However, we did not find an
association between nAChR variants and nicotine addiction related
variables in our study population. Furthermore, the observed
association between nAChR variants and lung function decline
withstood correction for smoking status (current versus former
smokers), years-quit smoking and pack-years smoked. Nicotinic
acetylcholine receptors (nAChRs), which are encoded by the
CHRNA genes, are also widely expressed on airway epithelial cells
and immune cells, such as macrophages, and their role in
mediating inflammatory processes has been established [25,26]. It
is therefore possible that nAChRs directly affect lung parenchyma
and that genetic variation modulates the inflammatory response
upon stimulation of nAChRs by its agonists, thereby determining
the extent of lung function decline. To completely discriminate
between a direct and indirect effect, the relationship between the
15q24/25 locus and COPD could be studied among never-
smokers. However, this approach is difficult given the very small
number of never-smoking COPD patients. Alternatively, new
statistical approaches could be applied, such as for instance
mediation analysis. By use of this technique, Wang et al.
established a direct association between rs1051730 and COPD
risk (P = 0.046), but also an indirect effect mediated by the
variability in smoking behavior according to rs1051730 genotypes
(0.006) [27]. These findings are similar to our results: we did not
establish an association between the 15q24/25 locus and nicotine
addiction related variables. However, we demonstrated that
rs1051730 affects lung function decline only in the group of
active smokers, suggesting that this SNP exerts a mediating, but
not a causal influence of smoking behavior. The hypothesis of a
dual association (direct and indirect via smoking behavior)
between 15q24/25, lung function decline and COPD should be
investigated in future studies.
Moreover, since our study was performed in subjects from
Caucasian ancestry, we cannot make any assumptions on the
association between nAChR variants and lung function parame-
ters or COPD in other ethnic groups. In a recent study in a
Chinese Han population, no significant association was found
between rs1051730 or rs8034191 and COPD in either former or
current smokers. On the other hand, rs8034191 and rs1051730
were both associated with FEV1% predicted and FEV1/FVC in
COPD cases [28].
The biology, by which rs1051730 and rs8034191 contribute to
smoking-related disease phenotypes still remains unresolved. The
rs1051730 SNP is a synonymous SNP located in exon 5 of the
CHRNA3 gene, which is in strong linkage disequilibrium with a
non-synonymous variant rs16969968 in exon 5 of the CHRNA5
gene [29] and with rs55853698 in the promoter region of
CHRNA 5 (all pairwise r2.0,96; figure 1) [30]. The SNP
rs16969968 results in an amino acid change (D398N) in the
alpha5 receptor subunit protein and has been shown to affect
receptor function [31]. The location of the rs55853698 variant
makes it a candidate for affecting mRNA transcription. On the
other hand, rs1051730 and rs8034191 are also strongly linked with
rs2568494 in the IREB2 gene (r2 = 0.692 and r2 = 0.790,
respectively; figure 1). Therefore genetic variation in the 15q24/
25 region can also result in an altered function of the IREB2 gene.
The finding of increased IREB2 protein and mRNA in lung-tissue
samples from COPD subjects in comparison to controls supports a
role of the IREB2 gene in COPD pathogenesis [32]. Additional
functional analyses are therefore required to establish whether the
CHRNA3, CHRNA5 or IREB2 genes are involved in COPD
development. Moreover, not only genetic variation, but also the
impact of epigenetic variation in these genes on the development
of COPD should be investigated. For instance in lung cancer, it
has been shown that the CHRNA3 gene is frequently hyper-
methylated in lung tumor tissue samples (in comparison with blood
control samples) and that this hypermethylation, by inducing gene
silencing, results in resistance against nicotine-induced apoptosis
[33].
Regardless of the mechanisms by which nAChR variants
predispose to an accelerated lung function decline in smokers,
the identification of this genetic locus could have important clinical
implications. First of all, this marker would contribute to the
prospective identification of a subset of susceptible smokers at high
risk for an accelerated loss of lung function. Secondly, since
smoking cessation is the most effective way to reduce the rate of
lung function decline, this information could be used to convince
subjects to quit smoking before symptoms of COPD develop.
Remarkably, we did not identify a significant association between
genetic variation in the nAChR genes and FEV1 decline. However,
as also suggested in another genetic association study on COPD-
related phenotypes, it is likely that different genetic loci control
FEV1 and FEV1/FVC, since both parameters reflect a different
functional measure [34].
The major strength of the present study is that we were able to
access a large number of apparently healthy, but heavy smokers, as
well as a relatively large cohort of symptomatic COPD patients,
including a significant number of patients with end-stage lung
Table 6. Significance values of the interaction terms
genotype*lung function parameter in the multiple linear
regression model of lung function decline in COPACETIC.
Interaction term p-value Interaction term p-value
rs1051730 * FEV1/FVC 0.225 rs8034191* FEV1/FVC 0.310
rs1051730 * MEF50 0.248 rs8034191* MEF50 0.172
doi:10.1371/journal.pone.0053219.t006
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disease in need of lung transplantation. This enabled us to study
the role of nAChR genetic variants in various stages of COPD
severity. Furthermore, the large number of study participants
allowed extensive corrections for potentially confounding factors
such as pack-years and smoking status. Unfortunately, we were not
able to correct for smoking intensity (for instance cigarettes
smoked per day). Some other limitations need to be acknowledged
as well. First, COPACETIC only recruited heavy smokers and we
could therefore not assess the effects of the 15q24/25 locus in
subjects being exposed to less nicotine. Second, our follow-up
period was limited to three years and we only assessed lung
function level at two different time points. Third, in the
COPACETIC cohort only males were included. Future studies
should include females to assess the interaction between
rs1057130/rs8034191, smoking status and lung function decline
since it is known that differences in smoking behavior and resulting
lung function disturbances exist between the sexes. Lastly, we only
had information on the smoking status at baseline. In theory some
quitters could have started smoking again which could have
influenced our results.
In conclusion, we have demonstrated that in a European
population heavy smokers carrying homozygous at-risk alleles for
rs1051730 and rs8034191 in the nAChR locus are characterized by
an accelerated decline in lung function, possibly leading to an
increased risk of developing severe COPD. We thus provide one of
the first genetic markers predictive for lung function decline.
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